Johnson & Johnson (NYSE:JNJ) Shares Unloaded Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on April 21st. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Tokyo Electron OTCMKTS: TOELY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Anheuser-Busch InBev SA/NV NYSE: BUD on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Edwards Lifesciences NYSE: EW on 4/21/2025.
• Sold $1,001 - $15,000 in shares of HSBC NYSE: HSBC on 4/21/2025.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 4/21/2025.
• Sold $1,001 - $15,000 in shares of DSV A/S OTCMKTS: DSDVY on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Walmart NYSE: WMT on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Bank of America NYSE: BAC on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Thermo Fisher Scientific NYSE: TMO on 4/21/2025.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $1.76 during trading hours on Friday, hitting $151.37. The stock had a trading volume of 8,045,511 shares, compared to its average volume of 7,949,399. The company has a 50-day moving average of $156.27 and a two-hundred day moving average of $153.90. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $364.20 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.44%. Johnson & Johnson's dividend payout ratio is 57.84%.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $169.00 to $153.00 in a report on Tuesday. Morgan Stanley increased their target price on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 16th. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Finally, Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after buying an additional 1,561,036 shares during the last quarter. Northern Trust Corp boosted its position in Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock valued at $5,131,723,000 after buying an additional 130,645 shares during the last quarter. Norges Bank bought a new position in Johnson & Johnson in the 4th quarter valued at $4,390,037,000. Finally, Wellington Management Group LLP boosted its position in Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after buying an additional 431,205 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.